Apply for Funding

ヒット・トゥ・リードプログラム

Past RFP

GHIT Fund RFP Hit-to-Lead Platform 2018-002

The Hit-to-Lead Platform (HTLP) is designed to leverage medicinal chemistry expertise in Japan and facilitate access to Japanese companies or academic organizations’ relevant and diverse compounds for drugs development to address malaria, tuberculosis, Chagas disease, and Visceral leishmaniasis.

 

HTLP projects will focus on the aspect of the drug discovery and development process that progresses hits, identified through compound library screening, into lead compounds that can then be optimized into drug candidates. This platform will provide a bridge from early drug discovery to our product development platform that begins with the lead-optimization step.

 

The key requirement of the Hit-to-Lead Platform is to convert drug hits originated from Japanese compound libraries into lead series through a comprehensive assessment of chemical integrity, synthetic accessibility, scalability and novelty, functional behavior, and structure-activity relationships (SAR), as well as bio-physiochemical and absorption, distribution, metabolism and excretion (ADME) properties.

 

Interested applicants can find detailed information on the RFP and the Intent to Apply (ITA) form below. An ITA should be submitted first and upon an eligibility assessment, approved applicants will be notified and request to submit a full proposal to the GHIT Fund.


RFP and Intent to Apply

Key RFP Milestone Dates

RFP Release

August 1, 2018

Intent to Apply

No later than 10:00 am Tokyo time on September 3, 2018
Submit Intent to Apply form to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2018-002_Intent to Apply

Q&A

No later than 10:00 am Tokyo time on September 26, 2018
Submit questions to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2018-002_Questions

Full Proposal Due

No later than 10:00 am Tokyo time on October 3, 2018
Submit proposal to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2018-002_Proposal

Proposals Evaluation and Interview Processes

October 2018 - February 2019

Award Notification to All Applicants

February 2019

Investment Agreement Fully Executed (Awarded Proposals)

March 2019

GHIT Fund RFP Hit-to-Lead Platform 2018-001

The Hit-to-Lead Platform (HTLP) is designed to leverage medicinal chemistry expertise in Japan and facilitate access to Japanese companies or academic organizations’ relevant and diverse compounds for drugs development to address malaria, tuberculosis, Chagas disease, and Visceral leishmaniasis.

 

HTLP projects will focus on the aspect of the drug discovery and development process that progresses hits, identified through compound library screening, into lead compounds that can then be optimized into drug candidates. This platform will provide a bridge from early drug discovery to our product development platform that begins with the lead-optimization step.

The key requirement of the Hit-to-Lead Platform is to convert drug hits originated from Japanese compound libraries into lead series through a comprehensive assessment of chemical integrity, synthetic accessibility, scalability and novelty, functional behavior, and structure-activity relationships (SAR), as well as bio-physiochemical and absorption, distribution, metabolism and excretion (ADME) properties.

 

Interested applicants can find detailed information on the RFP and the Intent to Apply (ITA) form below. An ITA should be submitted first and upon an eligibility assessment, approved applicants will be notified and request to submit a full proposal to the GHIT Fund.


RFP and Intent to Apply

Key RFP Milestone Dates

RFP Release

June 8, 2018

Intent to Apply

No later than 10:00 am Tokyo time on June 15, 2018
Submit Intent to Apply form to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2018-001_Intent to Apply

Q&A

No later than 10:00 am Tokyo time on June 22, 2018
Submit questions to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2018-001_Questions

Full Proposal Due

No later than 10:00 am Tokyo time on June 29, 2018
Submit proposal to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2018-001_Proposal

Proposals Evaluation and Interview Processes

July 2018

Award Notification to All Applicants

July 2018

Investment Agreement Fully Executed (Awarded Proposals)

August 2018

GHIT Fund RFP Hit-to-Lead Platform 2017-001

The Hit-to-Lead Platform (HTLP) is designed to leverage medicinal chemistry expertise in Japan and facilitate access to Japanese companies or academic organizations’ relevant and diverse compounds for drugs development to address malaria, tuberculosis, Chagas disease, and Visceral leishmaniasis.

 

HTLP projects will focus on the aspect of the drug discovery and development process that progresses hits, identified through compound library screening, into lead compounds that can then be optimized into drug candidates. This platform will provide a bridge from early drug discovery to our product development platform that begins with the lead-optimization step.

 

The key requirement of the Hit-to-Lead Platform is to convert drug hits originated from Japanese compound libraries into lead series through a comprehensive assessment of chemical integrity, synthetic accessibility, scalability and novelty, functional behavior, and structure-activity relationships (SAR), as well as bio-physiochemical and absorption, distribution, metabolism and excretion (ADME) properties.

 

Interested applicants can find detailed information on the RFP and the Intent to Apply (ITA) form below. An ITA should be submitted first and upon an eligibility assessment, approved applicants will be notified and request to submit a full proposal to the GHIT Fund.


RFP and Intent to Apply

Key RFP Milestone Dates

RFP Release

July 25, 2017

Intent to Apply

No later than 10:00 am Tokyo time on September 1, 2017

Submit Intent to Apply form to HTLPResponse@ghitfund.org

Email Subject Line: GHIT-RFP-HTLP-2017-001_Intent to Apply

Q&A

No later than 10:00 am Tokyo time on September 20, 2017

Submit questions to HTLPResponse@ghitfund.org

Email Subject Line: GHIT-RFP-HTLP-2017-001_Questions

Full Proposal Due

No later than 10:00 am Tokyo time on October 2, 2017

Submit proposal to HTLPResponse@ghitfund.org 

Email Subject Line: GHIT-RFP-HTLP-2017-001_Proposal

Proposals Evaluation and Interview Processes

October 2017 - January 2018

Award Notification to All Applicants

February 2018

Investment Agreement Fully Executed (Awarded Proposals)

March 2018

GHIT Fund RFP Hit-to-Lead Platform 2016-002

The Hit-to-Lead Platform (HTLP) is designed to leverage medicinal chemistry expertise in Japan and facilitate access to Japanese companies or academic organizations’ relevant and diverse compounds for drugs development to address malaria, tuberculosis, Chagas disease, and Visceral leishmaniasis.

 

HTLP projects will focus on the aspect of the drug discovery and development process that progresses hits, identified through compound library screening, into lead compounds that can then be optimized into drug candidates. This platform will provide a bridge from early drug discovery to our product development platform that begins with the lead-optimization step.

 

The key requirement of the Hit-to-Lead Platform is to convert drug hits originated from Japanese compound libraries into lead series through a comprehensive assessment of chemical integrity, synthetic accessibility, scalability and novelty, functional behavior, and structure-activity relationships (SAR), as well as bio-physiochemical and absorption, distribution, metabolism and excretion (ADME) properties.

 

Interested applicants can find detailed information on the RFP and the Intent to Apply (ITA) form below.  An ITA should be submitted first and upon an eligibility assessment, approved applicants will be notified and request to submit a full proposal to the GHIT Fund.


RFP and Intent to Apply

Key RFP Milestone Dates

RFP Release

August 1, 2016

Intent to Apply

No later than 10:00 am Tokyo time on September 1, 2016

 

Submit Intent to Apply form to HTLPResponse@ghitfund.org

 

Email Subject Line: GHIT-RFP-HTLP-2016-002_Intent to Apply

Q&A

No later than 10:00 am Tokyo time on September 20, 2016

 

Submit RFP questions to HTLPResponse@ghitfund.org

 

Email Subject Line: GHIT-RFP-HTLP-2016-002_Questions

Full Proposal Due

No later than 10:00 am Tokyo time on October 3, 2016

 

Submit proposal to HTLPResponse@ghitfund.org

 

Email Subject Line: GHIT-RFP-HTLP-2016-002_Proposal

Proposals Evaluation and Interview Processes

October 2016 - January 2017

Award Notification to All Applicants

No later than February 1, 2017

Investment Agreement Fully Executed (Awarded Proposals)

No later than March 31, 2017

GHIT Fund RFP Hit-to-Lead Platform 2016-001

The GHIT Fund endeavors to further facilitate collaboration & funding of global health technology R&D, to build momentum, and to demonstrate action and results. The Hit-to-Lead Platform (HTLP) is designed to leverage the Product Development Partnerships (PDPs)’ active platform for neglected and tropical diseases in partnership with Japanese companies or academic organizations that have relevant compounds. The intention is to facilitate access to the chemical diversity in Japanese research organizations and to the medicinal chemistry expertise in Japan.

 

If you are interested in applying for the platform, please see RFP.


RFP and Intent to Apply

Key RFP Milestone Dates

RFP Release

February 26, 2016

Intent to Apply

No later than 10:00 am Tokyo time on March 28, 2016

 

Submit Intent to Apply form to HTLPResponse@ghitfund.org

 

Email Subject Line: GHIT-RFP-HTLP-2016-001_Intent to Apply

Q&A

No later than 10:00 am Tokyo time on April 18, 2016

 

Submit questions to HTLPResponse@ghitfund.org

 

Email Subject Line: GHIT-RFP-HTLP-2016-001_Questions

Full Proposal Due

No later than 10:00 am Tokyo time on April 27, 2016

 

Submit proposal to HTLPResponse@ghitfund.org Email

 

Subject Line: GHIT-RFP-HTLP-2016-001_Proposal

Award Notification to All Applicants

No later than August 1, 2016

GHIT Fund RFP Hit-to-Lead Platform 2015-002

The GHIT Fund endeavors to further facilitate collaboration & funding of global health technology R&D, to build momentum, and to demonstrate action and results. The Hit-to-Lead Platform (HTLP) is designed to leverage the Product Development Partnerships (PDPs)’ active platform for neglected and tropical diseases in partnership with Japanese companies or academic organizations that have relevant compounds. The intention is to facilitate access to the chemical diversity in Japanese research organizations and to the medicinal chemistry expertise in Japan.

 

If you are interested in applying for the platform, please see RFP.


RFP and Intent to Apply

Key RFP Milestone Dates

RFP Release

August 12, 2015

Intent to Apply
No later than 10:00 am Tokyo time on October 5, 2015
 
Submit Intent to Apply form to HTLPResponse@ghitfund.org
 
Email Subject Line: GHIT-RFP-HTLP-2015-002_Intent to Apply
Q&A
No later than 10:00 am Tokyo time on November 2, 2015
 
Submit questions to  HTLPResponse@ghitfund.org
 
Email Subject Line: GHIT-RFP-HTLP-2015-002_Questions
Full Proposal Due
No later than 10:00 am Tokyo time on November 9, 2015
 
Submit questions to  HTLPResponse@ghitfund.org
 
Email Subject Line: GHIT-RFP-HTLP-2015-002_Proposal
Award Notification to All Applicants

No later than February 1, 2016

 

Investment Agreement :No later than March 1, 2016

GHIT Fund RFP Hit-to-Lead Platform 2015-001

The GHIT Fund endeavors to further facilitate collaboration & funding of global health technology R&D, to build momentum, and to demonstrate action and results. The Hit-to-Lead Platform (HTLP) is designed to leverage the Product Development Partnerships (PDPs)’ active platform for neglected and tropical diseases in partnership with Japanese companies or academic organizations that have relevant compounds. The intention is to facilitate access to the chemical diversity in Japanese research organizations and to the medicinal chemistry expertise in Japan.

 

If you are interested in applying for the platform, please see RFP.


RFP and Intent to Apply

Key RFP Milestone Dates

RFP Release

February 6, 2015

Intent to Apply
No later than 10:00 am Tokyo time on March 20, 2015
 
Submit Intent to Apply form to HTLPResponse@ghitfund.org
 
Email Subject Line: GHIT-RFP-HTLP-2015-001_Intent to Apply
Q&A
No later than 10:00 am Tokyo time on April 13, 2015
 
Submit questions to HTLPResponse@ghitfund.org
 
Email Subject Line: GHIT-RFP-HTLP-2015-001_Questions
Full Proposal Due
No later than 10:00 am Tokyo time on April 20, 2015
 
Submit proposal to HTLPResponse@ghitfund.org
 
Email Subject Line: GHIT-RFP-HTLP-2015-001_Proposal
Award Notification to All Applicants

No later than August 1, 2015

GHIT Fund RFP Hit-to-Lead Platform 2014-002

The GHIT Fund endeavors to further facilitate collaboration & funding of global health technology R&D, to build momentum, and to demonstrate action and results. The Hit-to-Lead Platform (HTLP) is designed to leverage the Product Development Partnerships (PDPs)’ active platform for neglected and tropical diseases in partnership with Japanese companies or academic organizations that have relevant compounds. The intention is to facilitate access to the chemical diversity in Japanese research organizations and to the medicinal chemistry expertise in Japan.


RFP and Intent to Apply

Key RFP Milestone Dates

RFP Release

August 6, 2014

Intent to Apply

10:00 am September 10, 2014

Submit GHIT_HTLP_RFP2014-002_Intent_To_Apply.docx to HTLPResponse@ghitfund.org

Email Subject Line: GHIT-HTLP_RFP-2014-002 Intent to Apply

Q&A

Submit Questions to HTLPResponse@ghitfund.org

Email Subject Line: GHIT-HTLP_RFP-2014-002 Questions

Full Proposal Due

10:00 am Tokyo Time October 10, 2014

Submit GHIT Fund HTLP Proposal, Timeline and Budget templates to HTLPResponse@ghitfund.org

Email Subject Line: GHIT-HTLP_RFP-2014-002 Proposal

Award Notification to All Applicants

No later than January 31, 2015

GHIT Fund RFP Hit-to-Lead Platform 2014-001

The GHIT Fund endeavors to further facilitate collaboration & funding of global health technology R&D, to build momentum, and to demonstrate action and results. The Hit-to-Lead Platform (HTLP) is designed to leverage the Product Development Partnerships (PDPs)’ active platform for neglected and tropical diseases in partnership with Japanese companies or academic organizations that have relevant compounds. The intention is to facilitate access to the chemical diversity in Japanese research organizations and to the medicinal chemistry expertise in Japan.


RFP and Intent to Apply

Key RFP Milestone Dates

RFP Release

March 17, 2014

Intent to Apply

10:00 am April 04, 2014
Submit GHIT Fund HTLP RFP2014-001 Intent To Apply to HTLPresponse@ghitfund.org
Email Subject Line: GHIT-HTLP_RFP-2014-001 Intent to Apply

Q&A

Submit Questions to HTLPresponse@ghitfund.org
Email Subject Line: GHIT-HTLP_RFP-2014-001 Questions

Full Proposal Due

10:00 am Tokyo Time April 30, 2014
Submit GHIT Fund HTLP RFP2014-001 to HTLPresponse@ghitfund.org
Email Subject Line: GHIT-HTLP_RFP-2014-001 Proposal

Award Notification to All Applicants

No later than July 15, 2014

|製品開発投資のプロセス

process1

申請者

Intent to Apply Formの提出

公募案件 (RFP)へ申請を希望する機関は、RFPの応募期間内に、Intent to Apply (ITA) FormをHTLPResponse@ghitfund.orgまで提出することが必須となります。ITA Formを提出した申請者には、受理確認メールが届きます。このプログラムでは、Product Development Partnerships (PDPs)であるMedicines for Malaria Venture (MMV), Drugs for Neglected Diseases initiative (DNDi), Global Alliance for TB Drug Development (GATB)のいずれかとのパートナーシップが必須となります。プロポーザルを提出する際に、これらのPDPsとのパートナーシップを確定させる必要があります。
※Intent to Apply (ITA)とは、プロポーザルを提出する前の段階で、GHIT Fundの公募案件に対して申請する意志をGHIT Fundに伝えることを指します。ITAの審査は、各RFP毎に個別かつ単独で行われているため、複数回応募、あるいは提出後の取り消しが以後のRFPにおける審査に影響を及ぼすことはありません。

process2

GHIT Fundマネジメントチーム

事前審査

ITA Formを提出した申請者には、受理確認のメールが届きます。GHIT Fundマネジメントチームが、提出されたITA Formの内容が申請要件の研究対象に沿ったものであるかを確認します。申請内容が申請要件に沿っていない場合は、申請プロジェクトの内容が審査対象外であることが申請者に伝えられます。指定された提出期限までに問題点を改善した場合には、ITA Formの再提出が可能です。

process3

申請者

プロポーザルの提出

申請者は書類一式に必要事項を記入し、期限までにHTLPResponse@ghitfund.orgへ提出する必要があります。一度提出されたプロポーザルは、修正することはできません。プロポーザル提出後は以下のような基準に基づいてGHIT Fundマネジメントチームが事前審査を行います。Proposalの審査は、各RFP毎に個別かつ単独で行われているため、複数回応募、あるいは提出後の取り消しが以後のRFPにおける審査に影響を及ぼすことはありません。

  • パートナーシップは、GHIT Fundの資格基準を満たしているか
  • プロジェクトの目的は、RFPに明記された研究対象の範囲に沿ったものであるか
  • プロポーザル一式がすべて揃い、書類に不備がないか
process4

HTLP エキスパート・パネル

プロポーザルの評価

事前審査を通過したプロポーザルは、以下の基準に基づいて、グローバルヘルス分野における基礎研究や製品開発の専門家で構成されるエキスパート・パネルで評価が行われ、投資案件候補の選定が行われます。

  • 科学的、および技術的価値(Scientific and technical merit)
  • 生み出されるインパクト(Potential Impact)
  • パートナーシップとプロジェクトマネジメント(Partnership and project management)
process5

HTLP サブ・コミティ

評価と投資案件の推薦

エキスパート・パネルで選定されたプロポーザルは、GHIT Fundの理事選考委員会のメンバーで構成されるHTLP サブ・コミティで改めて評価・承認が行われます。

process6

理事会

報告

サブ・コミティによって承認された案件に関しては、その後理事会に対して報告が行われます。理事会はポートフォリオ戦略を考慮した上で、リスクを最小限に抑えた上で成果を生み出すために、マイルストーンに基づいて投資を行います。

process7

GHIT Fundマネジメントチーム&製品開発パートナー

審査結果通知・契約締結・投資

投資案件決定の後、GHIT Fundマネジメントチームからすべての申請者に対して、メールにて選考結果を通知します。採択された案件の申請者は、採択通知が届いてから1ヶ月以内に、全製品開発パートナー署名済みのGHIT Fundとの契約書、並びに、各パートナーの役割と責任が明確に定義されたパートナー間の共同研究契約書をGHIT Fundに提出する必要があります。これらの条件が満たされない場合には契約が無効になる可能性がありますのでご注意ください。申請者は、製品開発パートナーの中から、代表機関(投資受領機関)を選択する必要があります。代表機関はプロジェクトの成果に対する責任を負い、代表機関における責任者は連絡窓口として、GHIT Fundとのコミュニケーションを行います。

process8

GHIT Fundマネジメントチーム

モニタリングと評価の開始

契約を締結しプロジェクトが開始すると、GHITマネジメントチームはモニタリングと評価を開始します。プロジェクトに関するデータと情報がシステム上で管理されます。

process9

GHIT Fundマネジメントチーム&製品開発パートナー

モニタリングと評価

投資案件の進捗状況を把握するため、GHIT Fundは年に2回、全ての投資案件の進捗確認を実施します。これにより、各案件におけるマイルストーンの達成度を確認し、投資の継続、変更、または終了の決定を行います。このモニタリングと評価を通じて、製品開発パートナーはウェブサイト上のシステムを用いて進捗報告を提出し、その報告をもとに、GHIT Fundマネジメントチームとの会議を行います。